Thursday, July 18, 2024 12:01:08 PM
Volume: | 581,070 |
Day Range: | 2.67 - 3.30 |
Bid: | 2.70 |
Ask: | 2.96 |
Last Trade Time: | 7:50:53 PM EST |
Total Trades: | 2,705 |
Recent SLRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2025 10:17:07 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/13/2025 01:36:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 01:09:31 PM
- Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement • GlobeNewswire Inc. • 01/13/2025 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/30/2024 05:15:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2024 05:22:37 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/16/2024 11:12:44 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/01/2024 09:05:56 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/01/2024 09:04:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 08:01:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:04:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:09:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:10:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 09:03:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/25/2024 09:01:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/22/2024 09:25:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 09:13:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 12:15:44 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/17/2024 12:11:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 12:05:28 PM
- Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:04:58 PM
- Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split • GlobeNewswire Inc. • 06/12/2024 12:00:00 PM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM
VOCODIA HOLDINGS INC. (OTCMKTS: VHAI) and TRACCOM INC. (OTCMKTS: TRCC) have signed an MOU to form a Joint Venture that will Revolutionize Event Monitoring with Narrative AI • VHAI • Jan 15, 2025 2:53 PM
UAV Corp (OTC: UMAV) Engages Legal Counsel to Initiate Uplisting Process with Ultimate Goal of NASDAQ Listing • UMAV • Jan 15, 2025 8:30 AM
HealthLynked Welcomes Jeremy Daniel as Chief Financial Officer • HLYK • Jan 15, 2025 8:00 AM
Zefiro Methane Corp. Subsidiary Awarded Slate of Government of Ohio-Funded Environmental Remediation Projects • ZEFI • Jan 15, 2025 7:33 AM